ClinicalTrials.gg
CompletedNCT03811912Updated Dec 9, 2022Results posted

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

A Phase 2 interventional study of CTP-543 and CTP-543 Matching Placebo in Alopecia Areata, sponsored by Concert Pharmaceuticals. Completed at 10 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-12-09.

Sponsored by Concert Pharmaceuticals (part of Sun Pharmaceutical Industries Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing deuruxolitinib in Alopecia Areata — 2 open to participants now, 3 under way, 3 of them phase 3. Deuruxolitinib · Alopecia Areata.

Enrollment
10th of 10
57 · median 336
Started
2019
with 2 others
Phase 2
4 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
6 of 10
Concert Pharmaceuticals

Among the 10 studies testing deuruxolitinib in Alopecia Areata, this one is the 10th largest by enrollment, is one of 3 that started in 2019, is one of 4 in phase 2, and was the 2nd registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

2 of the 10 studies testing deuruxolitinib in Alopecia Areata are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About deuruxolitinib

Deuruxolitinib: first FDA approval 2024 (LEQSELVI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing deuruxolitinib in Alopecia Areata, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.

03

Conditions studied

  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Definitive diagnosis of alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.
  • At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline.
  • Clinical lab results within the normal range

Exclusion criteria

Exclusion Criteria:

  • Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis on the scalp.
  • Treatment with systemic medications or biologics.
  • Vaccination with herpes zoster vaccine or any live virus within 6 weeks of screening or during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    CTP-543 8 mg BID

    Participants received 1 x 8 mg CTP-543 tablet and 1 x CTP-543 matching placebo tablet, twice daily (BID) for 24 weeks.

    Drug: CTP-543 · Drug: CTP-543 Matching Placebo

  • Experimental
    CTP-543 16 mg QD

    Participants received 16 mg (2 x 8 mg) CTP-543 tablets, once daily (QD) and after 12 hours, received 2 x CTP-543 matching placebo tablets, QD for 24 weeks.

    Drug: CTP-543 · Drug: CTP-543 Matching Placebo

Interventions

  • CTP-543 administered as 8 mg tablet.

  • DrugCTP-543 Matching Placebo

    Administered as tablets to aid treatment masking.

06

What researchers measure

Primary outcomes

  1. Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24

    The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[baseline SALT score - follow-up SALT score\]/baseline SALT score).

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Percentage of Participants Achieving at Least a 90%, 75%, and 50% Relative Reduction in SALT Score From Baseline

    The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Percentage of participants achieving at least a 50%, 75%, 90% relative reduction in SALT score from baseline at Weeks 4, 8, 12, 16, 20, and 24 are reported.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  2. Absolute Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24

    The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Absolute change equals the difference in SALT measurements (baseline SALT score - follow-up SALT score).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  3. Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16 and 20

    The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[baseline SALT score - follow-up SALT score\]/baseline SALT score).

    Time frame: Baseline, Weeks 4, 8, 12, 16 and 20

  4. Percentage of Participants With Change in Satisfaction of Hair Coverage

    Participant satisfaction question was used to assess overall satisfaction with hair coverage, with responses ranging from 1 to 5, as follows: 1 (very dissatisfied), 2 (dissatisfied), 3 (somewhat satisfied), 4 (mostly satisfied), 5 (very satisfied). Higher scores indicate better satisfaction with hair coverage. The percentage of participants with change from Baseline to the Week 24 satisfaction level was reported as categories: satisfied to satisfied; satisfied to dissatisfied; dissatisfied to satisfied and dissatisfied to dissatisfied. Data is reported only for participants with change from Baseline in satisfaction level.

    Time frame: Baseline, Week 24

Other outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety

    Time frame: 24 Weeks

07

Results

Posted Dec 9, 2022

Participant flow

Participants were enrolled at 10 study centers in the United States from 21 March 2019 to 21 November 2019.

Participant flow — Overall Study
MilestoneCTP-543 8 mg BIDCTP-543 16 mg QD
Started2928
Safety population2928
Completed2526
Not completed42
Withdrew: Withdrew consent42

Outcome measures

PrimaryRelative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24

The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[baseline SALT score - follow-up SALT score\]/baseline SALT score).

Time frame:
Baseline, Week 24
Reported as:
Mean · percent change
Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24
percent changeCTP-543 8 mg BIDCTP-543 16 mg QD
Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 2446.4 ± 38.2118.0 ± 32.32
SecondaryPercentage of Participants Achieving at Least a 90%, 75%, and 50% Relative Reduction in SALT Score From Baseline

The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Percentage of participants achieving at least a 50%, 75%, 90% relative reduction in SALT score from baseline at Weeks 4, 8, 12, 16, 20, and 24 are reported.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving at Least a 90%, 75%, and 50% Relative Reduction in SALT Score From Baseline
Percentage of participantsCTP-543 8 mg BIDCTP-543 16 mg QD
90% Reduction: Week 40 (0 to 1.7)0 (0 to 1.8)
90% Reduction: Week 80 (0 to 1.7)0 (0 to 1.8)
90% Reduction: Week 123.4 (0 to 10.7)0 (0 to 1.8)
90% Reduction: Week 166.9 (0 to 16.4)0 (0 to 1.8)
90% Reduction: Week 2013.8 (1.5 to 26.0)0 (0 to 1.8)
90% Reduction: Week 2420.7 (6.6 to 34.8)3.6 (0 to 11.1)
75% Reduction: Week 40 (0 to 1.7)0 (0 to 1.8)
75% Reduction: Week 83.4 (0 to 10.7)3.6 (0 to 11.1)
75% Reduction: Week 126.9 (0 to 16.4)0 (0 to 1.8)
75% Reduction: Week 1620.7 (6.6 to 34.8)3.6 (0 to 11.1)
75% Reduction: Week 2031.0 (15.2 to 46.9)10.7 (0 to 22.1)
75% Reduction: Week 2431.0 (15.2 to 46.9)10.7 (0 to 22.1)
50% Reduction: Week 40 (0 to 1.7)0 (0 to 1.8)
50% Reduction: Week 86.9 (0 to 16.4)3.6 (0 to 11.1)
50% Reduction: Week 1224.1 (9.3 to 38.9)7.1 (0 to 16.9)
50% Reduction: Week 1634.5 (18.2 to 50.7)14.3 (1.6 to 26.9)
50% Reduction: Week 2041.4 (24.6 to 58.1)14.3 (1.6 to 26.9)
50% Reduction: Week 2448.3 (31.3 to 65.3)17.9 (4.2 to 31.5)
SecondaryAbsolute Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24

The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Absolute change equals the difference in SALT measurements (baseline SALT score - follow-up SALT score).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · Score on a scale
Absolute Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24
Score on a scaleCTP-543 8 mg BIDCTP-543 16 mg QD
Change from Baseline at Week 40.8 ± 6.92-0.8 ± 4.49
Change from Baseline at Week 86.5 ± 15.022.1 ± 11.93
Change from Baseline at Week 1218.5 ± 23.275.3 ± 19.48
Change from Baseline at Week 1627.0 ± 29.319.4 ± 25.46
Change from Baseline at Week 2032.8 ± 29.2513.4 ± 28.06
Change from Baseline at Week 2437.7 ± 30.7515.7 ± 28.25
SecondaryRelative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16 and 20

The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[baseline SALT score - follow-up SALT score\]/baseline SALT score).

Time frame:
Baseline, Weeks 4, 8, 12, 16 and 20
Reported as:
Mean · percent change
Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16 and 20
percent changeCTP-543 8 mg BIDCTP-543 16 mg QD
Change from Baseline at Week 41.4 ± 9.67-1.3 ± 7.26
Change from Baseline at Week 88.6 ± 20.582.7 ± 19.43
Change from Baseline at Week 1223.7 ± 31.255.1 ± 22.91
Change from Baseline at Week 1633.3 ± 35.909.4 ± 28.85
Change from Baseline at Week 2040.6 ± 36.8514.8 ± 31.26
SecondaryPercentage of Participants With Change in Satisfaction of Hair Coverage

Participant satisfaction question was used to assess overall satisfaction with hair coverage, with responses ranging from 1 to 5, as follows: 1 (very dissatisfied), 2 (dissatisfied), 3 (somewhat satisfied), 4 (mostly satisfied), 5 (very satisfied). Higher scores indicate better satisfaction with hair coverage. The percentage of participants with change from Baseline to the Week 24 satisfaction level was reported as categories: satisfied to satisfied; satisfied to dissatisfied; dissatisfied to satisfied and dissatisfied to dissatisfied. Data is reported only for participants with change from Baseline in satisfaction level.

Time frame:
Baseline, Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Change in Satisfaction of Hair Coverage
Percentage of participantsCTP-543 8 mg BIDCTP-543 16 mg QD
Satisfied to Satisfied03.6
Satisfied to Dissatisfied3.40
Dissatisfied to Satisfied55.217.9
Dissatisfied to Dissatisfied34.575.0
Other pre-specifiedNumber of Participants With Adverse Events as a Measure of Safety
Time frame:
24 Weeks

Results for this outcome have not been posted.

Adverse events

Collected over Adverse Events: From first dose of study drug up to Week 28; All-cause mortality: Randomization up to Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CTP-543 8 mg BID0/29 (0%)0/29 (0%)23/29 (79.3%)
CTP-543 16 mg QD0/28 (0%)0/28 (0%)23/28 (82.1%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventCTP-543 8 mg BIDCTP-543 16 mg QD
HeadacheNervous system disorders8/295/28
NasopharyngitisInfections and infestations5/295/28
Upper respiratory tract infectionInfections and infestations5/293/28
AcneSkin and subcutaneous tissue disorders4/294/28
Weight increasedInvestigations1/293/28
ConstipationGastrointestinal disorders3/291/28
EcchymosisSkin and subcutaneous tissue disorders0/292/28
FallInjury, poisoning and procedural complications0/292/28
Throat irritationRespiratory, thoracic and mediastinal disorders0/292/28
Increased tendency to bruiseBlood and lymphatic system disorders0/292/28

Baseline characteristics

Randomized Population included all the randomized participants.

Age, Continuous
Age, Continuous(years)CTP-543 8 mg BIDCTP-543 16 mg QDTotal
Mean40.4 ± 12.9839.8 ± 13.6540.1 ± 13.20
Sex: Female, Male
Sex: Female, Male(Participants)CTP-543 8 mg BIDCTP-543 16 mg QDTotal
Female201838
Male91019
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CTP-543 8 mg BIDCTP-543 16 mg QDTotal
Hispanic or Latino347
Not Hispanic or Latino262450
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CTP-543 8 mg BIDCTP-543 16 mg QDTotal
Race — American Indian or Alaska Native000
Race — Asian213
Race — Black or African American033
Race — Native Hawaiian or Other Pacific Islander000
Race — White272350
Race — Other011
Region of Enrollment
Region of Enrollment(participants)CTP-543 8 mg BIDCTP-543 16 mg QDTotal
United States292857
Severity of Alopecia Tool (SALT) Score
Severity of Alopecia Tool (SALT) Score(score on a scale)CTP-543 8 mg BIDCTP-543 16 mg QDTotal
Mean87.1 ± 17.2390.4 ± 17.4688.7 ± 17.27
08

Study locations

10 sites
  • Investigative Site
    Irvine, California 92697, United States
  • Investigative Site
    San Francisco, California 94118, United States
  • Investigative Site
    New Haven, Connecticut 06519, United States
  • Investigative Site
    Boynton Beach, Florida 33472, United States
  • Investigative Site
    Boston, Massachusetts 02114, United States
  • Investigative Site
    Boston, Massachusetts 02115, United States
  • Investigative Site
    Fridley, Minnesota 55432, United States
  • Investigative Site
    Portsmouth, New Hampshire 03801, United States
  • Investigative Site
    Winston-Salem, North Carolina 27104, United States
  • Investigative Site
    Portland, Oregon 97210, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Nov 2019, 8 months.

Results were first posted in Dec 2022, 3 years after primary completion. A results delay was requested in Nov 2020.

Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2019
First posted
Jan 22, 2019
StartActual
Mar 21, 2019
Primary completionActual
Nov 21, 2019
CompletionActual
Nov 21, 2019
Results delay requested
Nov 16, 2020
Results first posted
Dec 9, 2022
Last update
Dec 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03811912
Responsible party
Sponsor
First posted
Jan 22, 2019
Start date
Mar 21, 2019
Primary completion
Nov 21, 2019
Completion
Nov 21, 2019
Results posted
Dec 9, 2022
Last update
Dec 9, 2022

Study contacts

Colleen E Hamilton, MS
study director · Concert Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deuruxolitinib

Start the discussion